M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 8.5 PLN -0.7% Market Closed
Market Cap: 137.4m PLN
Have any thoughts about
Mabion SA?
Write Note

P/E
Price to Earnings

13.4
Current
8
Median
22.1
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
13.4
=
Market Cap
137.4m PLN
/
Net Income
10.2m PLN
All Countries
Close
Market Cap P/E
PL
Mabion SA
WSE:MAB
137.4m PLN 13.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 740.1
US
Abbvie Inc
NYSE:ABBV
310.2B USD 61
US
Amgen Inc
NASDAQ:AMGN
142B USD 33.4
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 910
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD -211.2
US
Epizyme Inc
F:EPE
94.1B EUR -472.7
AU
CSL Ltd
ASX:CSL
134.4B AUD 31.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD 16.8
US
Seagen Inc
F:SGT
39.3B EUR -54.7
NL
argenx SE
XBRU:ARGX
36B EUR -135.6
Earnings Growth P/E to Growth
PL
M
Mabion SA
WSE:MAB
Average P/E: 177.7
13.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.4
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
910
77%
11.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -211.2
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-168.3
2-Years Forward
P/E
-3.8
3-Years Forward
P/E
-5.3

See Also

Discover More